Magnetic Resonance Biomarkers in Neonatal Encephalopathy (MARBLE): a prospective multicountry study. Issue 9 (30th September 2015)

• Record Type: Journal Article
• Authors: Lally, Peter J; Pauliah, Shreela; Montaldo, Paolo; Chaban, Badr; Oliveira, Vania; Bainbridge, Alan; Soe, Aung; Pattnayak, Santosh; Clarke, Paul; Satodia, Prakash; Harigopal, Sundeep; Abernethy, Laurence J; Turner, Mark A; Huertas-Ceballos, Angela; Shankaran, Seetha; Thayyil, Sudhin
• Is Part Of: BMJ open. Volume 5:Issue 9(2015)
• Publication Date: 2015-09-30
• Subjects: NEONATOLOGY -- NEUROLOGY; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2015-008912
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Despite cooling, adverse outcomes are seen in up to half of the surviving infants after neonatal encephalopathy. A number of novel adjunct drug therapies with cooling have been shown to be highly neuroprotective in animal studies, and are currently awaiting clinical translation. Rigorous evaluation of these therapies in phase II trials using surrogate MR biomarkers may speed up their bench to bedside translation. A recent systematic review of single-centre studies has suggested that MR spectroscopy biomarkers offer the best promise; however, the prognostic accuracy of these biomarkers in cooled encephalopathic babies in a multicentre setting using different MR scan makers is not known. Methods and analysis: The MR scanners (3 T; Philips, Siemens, GE) in all the participating sites will be harmonised using phantom experiments and healthy adult volunteers before the start of the study. We will then recruit 180 encephalopathic infants treated with whole body cooling from the participating centres. MRI and spectroscopy will be performed within 2 weeks of birth. Neurodevelopmental outcomes will be assessed at 18–24 months of age. Agreement between MR cerebral biomarkers and neurodevelopmental outcome will be reported. The sample size is calculated using the 'rule of 10', generally used to calculate the sample size requirements for developing prognostic models. Considering 9 parameters, we require 9×10 adverse events, which suggest that a total sample size of 180 is required. Ethics and dissemination: Human Research Ethics Committee approvals have been received from Brent Research Ethics Committee (London), and from Imperial College London (Sponsor). We will submit the results of the study to relevant journals and offer national and international presentations. Trial registration number: Clinical Trials.gov Number: NCT01309711 .